« Return to News | Drug Sponsors

Eli Lilly in talks with Turkish generic drug company

Friday, September 2, 2011 01:23 PM

Eli Lilly is in talks to form a partnership with, and potentially invest in, Turkish generic-drug company Mustafa Nevzat Ilac Sanayii (MN Pharmaceuticals), the Wall Street Journal reported, citing people familiar with the matter, according to Reuters.

The talks, which are in an early stage, mark the latest effort by a big western multinational to tap emerging markets for growth.

The discussions with Indianapolis-based Lilly are currently focused only on a minority interest, the newspaper reported.

Both Lilly and MN Pharmaceuticals have lined up advisers in advance of a potential deal. Besides a foreign drug company, it is also possible MN could sell a stake to a Middle Eastern sovereign wealth fund, one of the people told the Journal.

A deal with MN Pharmaceuticals would give a foreign drug company access to local distribution, low-cost manufacturing, regulatory expertise and new products. Turkey also could serve as a springboard to fast-growing markets in Asia.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.